Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s stock price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.32 and traded as low as $5.84. Enanta Pharmaceuticals shares last traded at $5.88, with a volume of 166,938 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ENTA shares. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. Robert W. Baird reduced their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Price Performance

The firm has a 50-day simple moving average of $6.36 and a 200 day simple moving average of $8.32. The stock has a market capitalization of $125.44 million, a P/E ratio of -1.19 and a beta of 0.48.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly acquired 45,000 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now owns 846,638 shares of the company’s stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in Enanta Pharmaceuticals in the fourth quarter worth approximately $26,000. Tower Research Capital LLC TRC increased its position in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 2,274 shares during the last quarter. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth approximately $58,000. Squarepoint Ops LLC purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at $66,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $75,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.